Our 2000% Runner & More

Huge Moves in KC, SLQT:

As usual, to start things off this morning, we’ve got some updates on some excellent options calls we’ve made recently, both with an expiration date of next Friday.

We signaled the KC 09/17 $30-35 Calls on the morning of August 25th, and the SLQT 09/17 $7.50-10 Calls first appeared in our report last Tuesday. We have already updated readers on both of these plays, but they have both continued to press to new highs, increasing the total possible gains to which we’ve had access.

They were both multi-bag ideas already but the updated figures have really impressed, especially the KC $35’s which have soared more than 2000%. Here are those gains now: 

KC 09/17 $30-35 Calls 
$30: .60-6.00 (+900%)
$35: .10-2.40 (+2300%)

SLQT 09/17 $7.50-10 Calls
$7.50:
 1.80-5.40 (+200%)
$10: .40-2.85 (+612%)


Fresh Options Ideas: 
PATH 09/17 $65-55 Puts
COUP Weekly $265-275 Calls
KFY 09/17 $70-80 Calls
FBRX 10/15 $5-10 Calls


OTC Gainer: 

We’ve also been tracking MTRT, which had already made a considerable move for us, and has also tacked on a big new high that we wanted to relay to anyone who’s been following the stock along with us.

Metal Arts Company Inc. MTRT
1st Alert: Sept. 1st
Range: .5777-6.235
Gained: +979%


Extended Watchlist:
BRYYF, ISWH, MGUY, DRNG, TWOH, FRTN, BBIG, AEI, KDMN, GANX, IGC

CURR News Update & More

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

We’re looking back in on CURR this morning on the heels of a key PR released by the company that we would like to share with our readers. We have been following this stock for roughly a month, and this FDA IND approval news is by far the most exciting development yet.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. (>>View Full PR via OTCMARKETS)

In addition to familiarizing yourself with the company’s news update, we would recommend you take a couple of minutes to check out the video presentation of the CURR chart that we have provided below: 


______

Please direct any investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com


Fresh Options Ideas:
SPY 01/06 $368-367 Puts


Extended Watchlist: 
TSPG, WDLF, ISWH, USRM, OZSC, LBRMF